Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-08-29
2008-12-30
Robinson, Hope A (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S013000, C435S007100
Reexamination Certificate
active
07470519
ABSTRACT:
The invention relates to a diagnostic assay for selectively measuring levels of the 35kD form of thrombin-activatable fibrinolysis inhibitor (TAFIa or TAFIai), or a derivative or variant thereof, but not the TAFI proenzyme (TAFI) or the N-terminal activation peptide of TAFI.
REFERENCES:
patent: 5206161 (1993-04-01), Drayna et al.
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5474901 (1995-12-01), Drayna et al.
patent: 5593674 (1997-01-01), Drayna et al.
patent: 5952305 (1999-09-01), Pfeffer et al.
patent: 5985562 (1999-11-01), Morser et al.
patent: 5993815 (1999-11-01), Bajzar et al.
patent: 2002/0177560 (2002-11-01), Greenfiled et al.
patent: 2826962 (2003-01-01), None
patent: WO 98/55645 (1998-12-01), None
patent: WO 99/20260 (1999-04-01), None
Nagashima et al. (Thrombosis Research, vol. 981, pp. 333-342, May 2000.
Bouma et al., 1999, “Factor XI Dependent and Independent Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Plasma Associated with Clot Formation,”Thromb. Haemost. 82(6):1703-1708.
Schatteman et al., 1999, “Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma,”Clinical Chemistry 45(6):807-813.
Schneider et al., 2001, “Paradoxical Attenuation of Fibrinolysis by Reversible Inhibitors of TAFIa,”Blood 98(11):254a.
Antovic et al., 2001, Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A,:Haemophilia 7:557-560.
Bajzar et al., 1995, “Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor”, J. Biol. Chem. 270(24):14477-14484.
Boffa et al., 1998, “Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties”, J. Biol. Chem. 273(4):2127-2135.
Boffa et al., 2000, “Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor”, J. Biol. Chem. 275(17):12868-12878.
Boffa et al., 2001, “Thrombin Activatable Fibrinolysis Inhibitor (TAFI): Molecular Genetics of an Emerging Potential Risk Factor for Thrombotic Disorders”, Current Drug Targets 1:59-74.
Bouma et al., 2001, “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)”, Thrombosis Research 101:329-354.
Fava et al., 1994, “Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue”, J. Exp. Med. 180:341-346.
Hendriks et al., 1990, “Purification and characterization of a new arginine carboxypeptidase in human serum”, Biochim. Biophys. Acta 1034:86-92.
Klement et al., 1999, “A Novel Approach to Arterial Thrombolysis”, Blood 94(8):2735-2743.
Marx et al., Dec. 1-5, 2000, 42ndAnnual Meeting of the American Society of Hematology, San Francisco, CA (Database Accession No. PREV200100311714).
Mosnier et al., 2001, “Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation”, Thromb. Haemost. 86:1057-1064.
Mosnier et al., 2001, “The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration”, Thromb. Haemost. 86:1035-1039.
Mosnier et al., 2001, “The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis”, Thromb. Haemost. 86:1040-1046.
Seong et al., Dec. 1-5, 2000, 42ndAnnual Meeting of the American Society of Hematology, San Francisco, CA (Database Accession No. PREV200100308410).
Sumii et al., 2002, “Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats”, Stroke 33:831-836.
Taylor et al., 1985, “Whole blood clot lysis: in vitro modulation by activated protein C”, Thromb. Res. 37:639-649.
Wang et al., 1994, “Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen”, J. Biol. Chem. 269(22):15937-15944.
An Seong Soo A.
Greenfield Robert S.
American Diagnostica Inc.
Jones Day
Robinson Hope A
LandOfFree
Methods for detecting TAFIa or TAFIai does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting TAFIa or TAFIai, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting TAFIa or TAFIai will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024680